Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2
Renal cell carcinoma (RCC) is one of the most common malignant tumors affecting the urogenital system, accounting for 90% of renal malignancies. Traditional chemotherapy options are often the front-line choice of regimen in the treatment of patients with RCC, but responses may be modest or limited d...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-09-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383518308505 |
| _version_ | 1818096830668341248 |
|---|---|
| author | Lu Chen Le Chen Zhiyuan Qin Jinxiu Lei Sheng Ye Kui Zeng Hua Wang Meidan Ying Jianqing Gao Su Zeng Lushan Yu |
| author_facet | Lu Chen Le Chen Zhiyuan Qin Jinxiu Lei Sheng Ye Kui Zeng Hua Wang Meidan Ying Jianqing Gao Su Zeng Lushan Yu |
| author_sort | Lu Chen |
| collection | DOAJ |
| description | Renal cell carcinoma (RCC) is one of the most common malignant tumors affecting the urogenital system, accounting for 90% of renal malignancies. Traditional chemotherapy options are often the front-line choice of regimen in the treatment of patients with RCC, but responses may be modest or limited due to resistance of the tumor to anticarcinogen. Downregulated expression of organic cation transporter OCT2 is a possible mechanism underlying oxaliplatin resistance in RCC treatment. In this study, we observed that miR-489-3p and miR-630 suppress OCT2 expression by directly binding to the OCT2 3′-UTR. Meanwhile, via 786-O-OCT2-miRNAs stable expression cell models, we found that miRNAs could repress the classic substrate 1-methyl-4-phenylpyridinium (MPP+), fluorogenic substrate N,N-dimethyl-4-(2-pyridin-4-ylethenyl) aniline (ASP+), and oxaliplatin uptake by OCT2 both in vitro and in xenografts. In 33 clinical samples, miR-489-3p and miR-630 were significantly upregulated in RCC, negatively correlating with the OCT2 expression level compared to that in adjacent normal tissues, using tissue microarray analysis and qPCR validation. The increased binding of c-Myc to the promoter of pri-miR-630, responsible for the upregulation of miR-630 in RCC, was further evidenced by chromatin immunoprecipitation and dual-luciferase reporter assay. Overall, this study indicated that miR-489-3p and miR-630 function as oncotherapy-obstructing microRNAs by directly targeting OCT2 in RCC. KEY WORDS: OCT2, miRNA, Renal cell carcinoma, Epigenetic regulation, Oxaliplatin |
| first_indexed | 2024-12-10T23:10:52Z |
| format | Article |
| id | doaj.art-fc12bb3436c04f4a9b3c659371c83270 |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-12-10T23:10:52Z |
| publishDate | 2019-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-fc12bb3436c04f4a9b3c659371c832702022-12-22T01:29:57ZengElsevierActa Pharmaceutica Sinica B2211-38352019-09-019510081020Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2Lu Chen0Le Chen1Zhiyuan Qin2Jinxiu Lei3Sheng Ye4Kui Zeng5Hua Wang6Meidan Ying7Jianqing Gao8Su Zeng9Lushan Yu10Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaInstitute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaInstitute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaInstitute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaPaediatric Intensive Care Unit, the Children׳s Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaInstitute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaDepartment of Urology, Cancer Hospital of Zhejiang Province, Hangzhou 310022, ChinaInstitute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaInstitute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaInstitute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaInstitute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Corresponding author. Tel.: +86 571 88208407; fax: +86 571 88208407.Renal cell carcinoma (RCC) is one of the most common malignant tumors affecting the urogenital system, accounting for 90% of renal malignancies. Traditional chemotherapy options are often the front-line choice of regimen in the treatment of patients with RCC, but responses may be modest or limited due to resistance of the tumor to anticarcinogen. Downregulated expression of organic cation transporter OCT2 is a possible mechanism underlying oxaliplatin resistance in RCC treatment. In this study, we observed that miR-489-3p and miR-630 suppress OCT2 expression by directly binding to the OCT2 3′-UTR. Meanwhile, via 786-O-OCT2-miRNAs stable expression cell models, we found that miRNAs could repress the classic substrate 1-methyl-4-phenylpyridinium (MPP+), fluorogenic substrate N,N-dimethyl-4-(2-pyridin-4-ylethenyl) aniline (ASP+), and oxaliplatin uptake by OCT2 both in vitro and in xenografts. In 33 clinical samples, miR-489-3p and miR-630 were significantly upregulated in RCC, negatively correlating with the OCT2 expression level compared to that in adjacent normal tissues, using tissue microarray analysis and qPCR validation. The increased binding of c-Myc to the promoter of pri-miR-630, responsible for the upregulation of miR-630 in RCC, was further evidenced by chromatin immunoprecipitation and dual-luciferase reporter assay. Overall, this study indicated that miR-489-3p and miR-630 function as oncotherapy-obstructing microRNAs by directly targeting OCT2 in RCC. KEY WORDS: OCT2, miRNA, Renal cell carcinoma, Epigenetic regulation, Oxaliplatinhttp://www.sciencedirect.com/science/article/pii/S2211383518308505 |
| spellingShingle | Lu Chen Le Chen Zhiyuan Qin Jinxiu Lei Sheng Ye Kui Zeng Hua Wang Meidan Ying Jianqing Gao Su Zeng Lushan Yu Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2 Acta Pharmaceutica Sinica B |
| title | Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2 |
| title_full | Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2 |
| title_fullStr | Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2 |
| title_full_unstemmed | Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2 |
| title_short | Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2 |
| title_sort | upregulation of mir 489 3p and mir 630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting oct2 |
| url | http://www.sciencedirect.com/science/article/pii/S2211383518308505 |
| work_keys_str_mv | AT luchen upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT lechen upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT zhiyuanqin upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT jinxiulei upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT shengye upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT kuizeng upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT huawang upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT meidanying upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT jianqinggao upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT suzeng upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 AT lushanyu upregulationofmir4893pandmir630inhibitsoxaliplatinuptakeinrenalcellcarcinomabytargetingoct2 |